Boston Scientific Catheter Says Trial Meets Safety, Effectiveness Goals
MT Newswires Live
May 19
Boston Scientific (BSX) said Tuesday that a clinical trial evaluating its investigational catheter for treating severe coronary artery disease met primary safety and effectiveness endpoints.
The study of 420 patients demonstrated a 93.3% rate of freedom from major adverse cardiac events at 30 days alongside a 93.7% procedural success rate, the company said.
Physicians achieved complete stent delivery success and a 94.2% average expansion rate at the most calcified arterial segments using the device, it said.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.